CRISPR Therapeutics AG
CRSP · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.10 | -0.02 | 0.40 | 0.36 |
| FCF Yield | -2.69% | -1.85% | -1.49% | -2.68% |
| EV / EBITDA | -20.99 | -20.24 | -55.05 | -38.01 |
| Quality | ||||
| ROIC | -6.83% | -7.25% | -3.03% | -5.06% |
| Gross Margin | -5,477.69% | -6,548.44% | 100.00% | -1,752.66% |
| Cash Conversion Ratio | 0.80 | 0.55 | 0.40 | 1.34 |
| Growth | ||||
| Revenue 3-Year CAGR | -39.98% | -40.48% | -28.67% | 335.54% |
| Free Cash Flow Growth | -110.51% | -7.69% | 53.06% | -11.26% |
| Safety | ||||
| Net Debt / EBITDA | -0.09 | 0.11 | 1.25 | -0.02 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -17.64 | -20.44 | 64.29 | -125.71 |